Daewoong KRX:003090KOSPI
대웅 · Korean news coverage and regulatory filings, organized.
Articles, 24h3
Articles, 7 days4
DART filings, 7 days0
Articles tracked4since Sep 11
In Q2 2026, Daewoong reported revenue of ₩571bn, up 8.0% year on year, and operating profit of ₩76.6bn. Daewoong (대웅) appeared in 4 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Sep 14 with 2 articles. It was most often mentioned alongside Chong Kun Dang Pharmaceutical, Hugel and Medy-Tox.
Daewoong quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩571bn | +8.0% | ₩76.6bn | ₩36.3bn |
| Q1 2026 | ₩493bn | +2.3% | ₩47.8bn | ₩53.3bn |
| Q4 2025 derived | ₩516bn | – | ₩34.8bn | ₩69.4bn |
| Q3 2025 | ₩542bn | – | ₩80.5bn | ₩62.7bn |
| Q2 2025 | ₩528bn | +11.6% | ₩85.3bn | ₩61.3bn |
| Q1 2025 | ₩481bn | +8.5% | ₩61.1bn | ₩34.5bn |
| Q4 2024 derived | – | – | ₩63.0bn | −₩32.5bn |
| Q3 2024 | – | – | ₩102bn | ₩58.0bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
Daewoong top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
